Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637693 | 0.83 | KDM2B (0.51) | — | |
| SCHEMBL15636566 | 0.81 | KDM2B (0.49) | — | |
| SCHEMBL17710855 | 0.81 | CXCR4 (0.60) | SLC6A4 | |
| SCHEMBL15636850 | 0.78 | DRD4 (0.55) | — | |
| SCHEMBL4777009 | 0.78 | CCR3 (0.65) | CCR3SLC6A2SLC6A4 | |
| SCHEMBL16291811 | 0.77 | KDM5C (0.51) | — | |
| SCHEMBL4773788 | 0.75 | CCR3 (0.55) | CCR3 | |
| SCHEMBL5914321 | 0.75 | CCR3 (0.68) | CCR3SLC6A2SLC6A4 | |
| SCHEMBL15637048 | 0.74 | DRD4 (0.50) | — | |
| SCHEMBL15637052 | 0.74 | DRD4 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9611219-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| US-9611219-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| EP-2903968-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2903968-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189787-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | CCR3 4435/4885SLC6A2 4615/4885SLC6A4 4462/4885 |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | CCR3 4453/4885SLC6A2 4617/4885SLC6A4 4467/4885 |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | CCR3 4435/4885SLC6A2 4615/4885SLC6A4 4462/4885 |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | CCR3 4435/4885SLC6A2 4615/4885SLC6A4 4462/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | CCR3 4435/4885SLC6A2 4615/4885SLC6A4 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.